Magic Mushroom Compound Shows Promise In Preventing Painful Chemotherapy Nerve Damage

Magic Mushroom Compound Shows Promise in Preventing Painful Chemotherapy Nerve Damage Scientists are exploring an unexpected potential use for psilocybin, the psychedelic compound found in so-called magic mushrooms, after a new study found that it may help prevent one of the painful side effects associated with chemotherapy. The research, published in the journal Science, found that giving psilocybin before chemotherapy prevented the development of chemotherapy-induced peripheral neuropathy in preclinical models. Researchers also examined certain human tissues as they investigated how the compound may protect nerves. Peripheral neuropathy occurs when chemotherapy damages nerves outside the brain and spinal cord. The condition can cause numbness, tingling, heightened sensitivity to cold, loss of sensation and persistent burning pain, particularly in the hands and feet. In severe cases, the symptoms can affect mobility and may continue long after cancer treatment has ended. Patrick Dougherty, a study co-author and pain treatment specialist at the University of Texas MD Anderson Cancer Center, said the condition affects roughly three-quarters of people undergoing chemotherapy, with about one third of those patients developing persistent burning pain. The complications can be serious enough that some patients require reductions in their chemotherapy doses or have treatment stopped altogether, potentially affecting their chances of survival.Researchers at the University of Texas MD Anderson Cancer Center discovered that psilocybin administered before chemotherapy prevented nerve injury in several preclinical models. In mice, two doses given before chemotherapy prevented hypersensitivity to cold, preserved normal touch sensation and protected sensory nerve endings even after repeated chemotherapy cycles. Importantly, researchers found no evidence that the treatment reduced chemotherapy’s ability to attack tumours. The findings suggest that psilocybin could potentially be used as a preventative treatment rather than attempting to manage nerve damage after it has already developed. Scientists believe psilocybin’s protective effect is linked to serotonin 5-HT2A receptors found on sensory nerve fibres. The researchers found that activating this pathway helped maintain the movement and distribution of mitochondria structures often described as the energy-producing centres of cells within nerve cells. Chemotherapy can disrupt this process, depriving nerve endings of energy and contributing to nerve degeneration. Psilocybin appeared to help preserve the cellular energy supply and prevent that damage in the laboratory models. One of the more intriguing aspects of the research is that scientists found evidence that the nerve-protective effect may not depend on psilocybin’s hallucinogenic properties. Researchers tested a non hallucinogenic compound called tabernanthalog, which activates the same receptor pathway. The compound produced similar protective effects against sensory nerve loss and pain hypersensitivity in the animal models. That finding could eventually open the door to developing treatments that provide the biological benefits associated with the pathway without producing the psychedelic experience normally associated with psilocybin.Despite the encouraging results, scientists stress that the research is still at the preclinical stage. The findings were primarily obtained from animal models, alongside laboratory work involving human tissues. They do not establish that taking psilocybin will prevent chemotherapy-related nerve damage in cancer patients. Human clinical trials are needed to determine whether the treatment is safe and effective. A Phase 2 clinical trial is being developed to investigate whether psilocybin can prevent or reduce chemotherapy-induced peripheral neuropathy in patients being treated for several types of cancer. The US National Cancer Institute lists the trial as approved and focused on patients with breast, colorectal and head and neck cancers. The study’s researchers say there is an urgent need for treatments that can prevent nerve injury without interfering with chemotherapy’s cancer-fighting effects. Dr Moran Amit of MD Anderson, who led the research, said the findings point towards protecting nerves before chemotherapy causes lasting damage rather than attempting to reverse established neuropathy. If future human trials confirm the results, the research could eventually lead to a new strategy for protecting cancer patients from one of chemotherapy’s most persistent and debilitating complications. For now, however, psilocybin remains an experimental research avenue and should not be considered an established treatment for chemotherapy-related nerve damage.